secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001558370-25-006482
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Q1 2025 net loss $31.0M, revenue down 67% YoY; cash $295M into mid-2027
-------------------------------------------------------------------------------

- Net loss $31.0M vs $11.3M YoY; collaboration revenue $6.5M vs $19.5M YoY (−67%).
- Cash, cash equivalents & marketable securities $295M; expects runway into mid-2027.
- R&D expenses $31.5M (+16% YoY); G&A $9.6M (+12% YoY).
- VY1706 tau silencing gene therapy achieved up to 73% tau mRNA knockdown in NHPs; IND/CTA filings expected 2026.
- Neurocrine-partnered FA and GBA1 IND submissions on track for 2025; up to $35M milestone potential 2025-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000155837025006482/0001558370-25-006482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000155837025006482/vygr-20250506x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-006482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer